UA90269C2 - Тетрагидрохинолиновые производные и способ их получения - Google Patents
Тетрагидрохинолиновые производные и способ их полученияInfo
- Publication number
- UA90269C2 UA90269C2 UAA200611525A UAA200611525A UA90269C2 UA 90269 C2 UA90269 C2 UA 90269C2 UA A200611525 A UAA200611525 A UA A200611525A UA A200611525 A UAA200611525 A UA A200611525A UA 90269 C2 UA90269 C2 UA 90269C2
- Authority
- UA
- Ukraine
- Prior art keywords
- ris
- alkyl
- preparing
- optionally substituted
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004109550 | 2004-04-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
UA90269C2 true UA90269C2 (ru) | 2010-04-26 |
Family
ID=34963484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200611525A UA90269C2 (ru) | 2004-04-02 | 2005-01-04 | Тетрагидрохинолиновые производные и способ их получения |
Country Status (25)
Country | Link |
---|---|
US (2) | US7872126B2 (ru) |
EP (1) | EP1730152B1 (ru) |
JP (1) | JP4565077B2 (ru) |
KR (1) | KR100905684B1 (ru) |
CN (2) | CN100528878C (ru) |
AR (2) | AR048361A1 (ru) |
AT (1) | ATE556077T1 (ru) |
AU (1) | AU2005228290B2 (ru) |
BR (1) | BRPI0509364B8 (ru) |
CA (1) | CA2560402C (ru) |
DK (1) | DK1730152T3 (ru) |
EA (1) | EA011670B1 (ru) |
EC (1) | ECSP066967A (ru) |
ES (1) | ES2383900T3 (ru) |
IL (1) | IL178195A (ru) |
MX (1) | MXPA06011415A (ru) |
MY (1) | MY158055A (ru) |
NO (1) | NO20065011L (ru) |
NZ (1) | NZ550268A (ru) |
PL (1) | PL1730152T3 (ru) |
PT (1) | PT1730152E (ru) |
TW (1) | TWI338684B (ru) |
UA (1) | UA90269C2 (ru) |
WO (1) | WO2005095409A2 (ru) |
ZA (1) | ZA200608117B (ru) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060287254A1 (en) * | 2001-01-26 | 2006-12-21 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
MXPA06014716A (es) * | 2004-06-24 | 2007-03-12 | Lilly Co Eli | Compuestos y metodos para el tratamiento de dislipidemia. |
DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
US20060063803A1 (en) * | 2004-09-23 | 2006-03-23 | Pfizer Inc | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds |
WO2006069162A1 (en) | 2004-12-20 | 2006-06-29 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds and their pharmaceutical compositions |
CN101443006B (zh) | 2004-12-31 | 2012-10-10 | 雷迪美国治疗股份有限公司 | 作为cetp抑制剂的新颖的苄胺衍生物 |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
JP4531027B2 (ja) * | 2005-09-29 | 2010-08-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
WO2007048027A2 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
US7790770B2 (en) | 2005-11-23 | 2010-09-07 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
US7652023B2 (en) | 2005-11-23 | 2010-01-26 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
WO2007107843A1 (en) * | 2006-03-22 | 2007-09-27 | Pfizer Products Inc. | Methods of treatment with cetp inhibitors |
UY30244A1 (es) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
AR061644A1 (es) * | 2006-06-27 | 2008-09-10 | Takeda Pharmaceutical | Derivados de benzofurano |
US7582691B2 (en) * | 2007-01-17 | 2009-09-01 | Sabic Innovative Plastics Ip B.V. | Poly(arylene ether) compositions and articles |
JP4834699B2 (ja) * | 2007-07-30 | 2011-12-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
SI2207775T1 (sl) | 2007-11-05 | 2012-05-31 | Novartis Ag | benzilamino karboksiacil piperidinski derivati kot inhibitorji CETP uporabni za zdravljenje bolezni kot je hiperlipidemija ali arterioskleroza |
AU2012202172B2 (en) * | 2007-11-05 | 2013-08-29 | Novartis Ag | 4-benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis |
CN101878199B (zh) | 2007-12-03 | 2013-09-18 | 诺瓦提斯公司 | 用于治疗例如高血脂或动脉硬化疾病的作为cetp抑制剂的1,2-二取代的-4-苄基氨基-吡咯烷衍生物 |
EP2429995B1 (en) | 2009-05-15 | 2014-01-22 | Novartis AG | Aryl pyridine as aldosterone synthase inhibitors |
EA201101621A1 (ru) | 2009-05-15 | 2012-05-30 | Новартис Аг | Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы |
CA2763565A1 (en) | 2009-05-28 | 2010-12-02 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
ES2523734T3 (es) | 2009-05-28 | 2014-12-01 | Novartis Ag | Derivados aminopropiónicos sustituidos como inhibidores de neprilisina |
JP5654608B2 (ja) | 2009-11-17 | 2015-01-14 | ノバルティス アーゲー | アルドステロンシンターゼ阻害剤としてのアリール−ピリジン誘導体 |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
CN102666535B (zh) | 2009-11-30 | 2015-02-25 | 诺华股份有限公司 | 作为醛固酮合酶抑制剂的咪唑衍生物 |
EP2592076B1 (en) * | 2010-07-09 | 2015-05-13 | Daiichi Sankyo Company, Limited | Substituted pyridine compound |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
JP5964965B2 (ja) | 2011-08-18 | 2016-08-03 | ドクター レディズ ラボラトリーズ リミテッド | コレステリルエステル転送タンパク質(cetp)インヒビターとしての置換複素環式アミン化合物 |
KR101803866B1 (ko) | 2011-09-27 | 2017-12-04 | 닥터 레디스 레보러터리즈 리미티드 | 동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체 |
TWI570118B (zh) * | 2012-01-06 | 2017-02-11 | 第一三共股份有限公司 | 經取代之吡啶化合物的酸加成鹽 |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
LT2956464T (lt) | 2013-02-14 | 2018-07-10 | Novartis Ag | Pakeisti bisfenilbutanoinės fosfonrūgšties dariniai, kaip nep (neutralios endopeptidazės) inhibitoriai |
MX2016001021A (es) | 2013-07-25 | 2016-08-03 | Novartis Ag | Bioconjugados de polipeptidos de apelina sinteticos. |
TN2016000031A1 (en) | 2013-07-25 | 2017-07-05 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
CN110721187A (zh) * | 2014-02-05 | 2020-01-24 | 田边三菱制药株式会社 | 用于治疗或预防心血管疾病的胆固醇酯转移蛋白(cetp)抑制剂和含所述抑制剂的药物组合物 |
EP4083022A1 (en) * | 2014-08-12 | 2022-11-02 | NewAmsterdam Pharma B.V. | Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives |
US10300059B2 (en) * | 2014-08-28 | 2019-05-28 | Dezima Pharma B.V. | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors |
AU2016209968B2 (en) | 2015-01-23 | 2018-11-29 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
WO2017023165A1 (en) | 2015-08-04 | 2017-02-09 | Dezima Pharma B.V. | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator |
WO2017023166A1 (en) | 2015-08-04 | 2017-02-09 | Dezima Pharma B.V. | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and a cholesterol absorption inhibitor |
JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
BR112023016682A2 (pt) * | 2021-02-18 | 2023-11-14 | Newamsterdam Pharma B V | Terapia de combinação de obicetrapibe e ezetimiba para uso em pacientes intolerantes a estatina sofrendo de hiperlipidemia ou dislipidemia mista |
CN117529319A (zh) * | 2021-03-05 | 2024-02-06 | 新阿姆斯特丹制药私人有限公司 | 用于治疗痴呆的奥比塞曲匹 |
CN113499860A (zh) * | 2021-07-08 | 2021-10-15 | 江西新金叶实业有限公司 | 一种铜再生回收冶炼渣高效浮选方法 |
IL310115A (en) | 2021-07-26 | 2024-03-01 | Newamsterdam Pharma B V | Treatment of sub-responders to high-dose statins |
AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
WO2023129595A1 (en) | 2021-12-30 | 2023-07-06 | Newamsterdam Pharma B.V. | Obicetrapib and sglt2 inhibitor combination |
TW202409008A (zh) | 2022-07-05 | 2024-03-01 | 荷蘭商新阿姆斯特丹製藥公司 | 奧比特拉(obicetrapib)鹽及彼等之製造方法與中間體 |
WO2024042061A1 (en) | 2022-08-22 | 2024-02-29 | Newamsterdam Pharma B.V. | Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2760237B1 (fr) * | 1997-02-28 | 1999-04-16 | Rhone Poulenc Rorer Sa | Thiazolobenzoheterocycles, leur preparation et les medicaments les contenant |
FR2763590B1 (fr) * | 1997-05-22 | 2000-03-24 | Synthelabo | Derives d'acides[[[(arylmethyl)amino]carbonyl] alkyl]- aromatiques, leur preparation et leur application en therapeutique |
GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6147090A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
HN2000000203A (es) * | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
JP2001348332A (ja) * | 2000-04-07 | 2001-12-18 | Takeda Chem Ind Ltd | 可溶性ベータ・アミロイド前駆蛋白質分泌促進剤 |
JP2002053557A (ja) * | 2000-08-14 | 2002-02-19 | Japan Tobacco Inc | アポリポ蛋白a−i産生促進薬 |
JP4245130B2 (ja) | 2000-12-18 | 2009-03-25 | アクテリオン ファーマシューティカルズ リミテッド | 新規なスルファミド類 |
SE0101161D0 (sv) * | 2001-03-30 | 2001-03-30 | Astrazeneca Ab | New compounds |
US20030216398A1 (en) * | 2001-04-05 | 2003-11-20 | Mitsuru Kakihana | Soluble beta amyloid precursor protein secretion promoters |
BR0307332A (pt) | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol |
MXPA06014716A (es) | 2004-06-24 | 2007-03-12 | Lilly Co Eli | Compuestos y metodos para el tratamiento de dislipidemia. |
JP4531027B2 (ja) * | 2005-09-29 | 2010-08-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
-
2005
- 2005-01-04 UA UAA200611525A patent/UA90269C2/ru unknown
- 2005-03-30 MY MYPI20051442A patent/MY158055A/en unknown
- 2005-03-30 TW TW094109940A patent/TWI338684B/zh active
- 2005-04-01 EP EP05728670A patent/EP1730152B1/en active Active
- 2005-04-01 BR BRPI0509364A patent/BRPI0509364B8/pt active IP Right Grant
- 2005-04-01 NZ NZ550268A patent/NZ550268A/en unknown
- 2005-04-01 KR KR1020067020435A patent/KR100905684B1/ko active IP Right Grant
- 2005-04-01 CN CNB2005800103986A patent/CN100528878C/zh active Active
- 2005-04-01 JP JP2006534487A patent/JP4565077B2/ja active Active
- 2005-04-01 PT PT05728670T patent/PT1730152E/pt unknown
- 2005-04-01 PL PL05728670T patent/PL1730152T3/pl unknown
- 2005-04-01 AU AU2005228290A patent/AU2005228290B2/en active Active
- 2005-04-01 MX MXPA06011415A patent/MXPA06011415A/es active IP Right Grant
- 2005-04-01 DK DK05728670.0T patent/DK1730152T3/da active
- 2005-04-01 WO PCT/JP2005/006894 patent/WO2005095409A2/en active Application Filing
- 2005-04-01 ES ES05728670T patent/ES2383900T3/es active Active
- 2005-04-01 AR ARP050101294A patent/AR048361A1/es active IP Right Grant
- 2005-04-01 CN CNA2008101454330A patent/CN101381345A/zh active Pending
- 2005-04-01 AT AT05728670T patent/ATE556077T1/de active
- 2005-04-01 EA EA200601852A patent/EA011670B1/ru not_active IP Right Cessation
- 2005-04-01 CA CA2560402A patent/CA2560402C/en active Active
-
2006
- 2006-09-19 IL IL178195A patent/IL178195A/en active IP Right Grant
- 2006-09-27 US US11/527,691 patent/US7872126B2/en active Active
- 2006-09-29 ZA ZA200608117A patent/ZA200608117B/xx unknown
- 2006-10-31 EC EC2006006967A patent/ECSP066967A/es unknown
- 2006-11-01 NO NO20065011A patent/NO20065011L/no not_active Application Discontinuation
-
2010
- 2010-10-25 US US12/911,149 patent/US8158640B2/en active Active
-
2017
- 2017-01-17 AR ARP170100115A patent/AR107377A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA90269C2 (ru) | Тетрагидрохинолиновые производные и способ их получения | |
MY139887A (en) | Tetrahydronaphthyridine derivatives and a process for preparing the same. | |
JO2994B1 (ar) | مثبطات البروتين الناقل لاستر الكولسترول ( cetp ) | |
WO2007081570A3 (en) | Cholesteryl ester transfer protein inhibitors | |
TW200800947A (en) | Trisubstituted amine compound | |
UA94424C2 (en) | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors | |
TW200637822A (en) | Process for the preparation of a 2-pyridylethylcarboxamide derivative | |
TW200640913A (en) | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | |
WO2003024967A3 (en) | Indolizines as kinase protein inhibitors | |
TW200633981A (en) | Process for the preparation of a 2-ethylaminopyridine derivative | |
HK1091831A1 (en) | Isoxazole compounds as inhibitors of heat shock proteins | |
EP1527049B8 (en) | Fused heterocyclic compounds as peptidase inhibitors | |
TW200635913A (en) | Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof | |
WO2008111604A1 (ja) | 新規なベンジル(ヘテロサイクリックメチル)アミン構造を有するピリミジン化合物及びこれを含有する医薬 | |
MX2013004407A (es) | Derivado de piridina y agente medicinal. | |
IL148932A0 (en) | INHIBITORS OF αLβ2 MEDIATED CELL ADHESION | |
WO2009018065A3 (en) | Novel glucokinase activators and methods of using same | |
TW200732281A (en) | Heterocyclic CETP inhibitors | |
IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
UA86077C2 (en) | Cetp inhibitors | |
TNSN08161A1 (en) | 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof | |
TW200510361A (en) | Process of preparating 3-acylaminobenzofuran-2-carboxylic acid derivatives | |
HK1094575A1 (en) | A process for the preparation of phenyltetrazole derivatives | |
PL361850A1 (en) | Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines | |
UA86574C2 (ru) | Фторированные производные бензотиадиазина, способ их получения и фармацевтическая композиция, которая их содержит |